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AbstrACt
Introduction End- of- life care is an essential task 
performed by most healthcare providers and often involves 
decision- making about how and where patients want to 
receive care. To provide decision support to healthcare 
professionals and patients in this difficult situation, we will 
systematically review a knowledge cluster of the end- of- 
life care preferences of older patients with multimorbidity 
that we previously identified using an evidence map.
Methods and analysis We will systematically search 
for studies reporting end- of- life care preferences of 
older patients (mean age ≥60) with multimorbidity (≥2 
chronic conditions) in MEDLINE, CINAHL, PsycINFO, 
Social Sciences Citation Index, Social Sciences Citation 
Index Expanded, PSYNDEX and The Cochrane Library 
from inception to September 2019. We will include all 
primary studies that use quantitative, qualitative and 
mixed methodologies, irrespective of publication date and 
language.
Two independent reviewers will assess eligibility, extract 
data and describe evidence in terms of study/population 
characteristics, preference assessment method and 
end- of- life care elements that matter to patients (eg, life- 
sustaining treatments). Risk of bias/applicability of results 
will be independently assessed by two reviewers using 
the Mixed- Methods Appraisal Tool. Using a convergent 
integrated approach on qualitative/quantitative studies, 
we will synthesise information narratively and, wherever 
possible, quantitatively.
Ethics and dissemination Due to the nature of the 
proposed systematic review, ethics approval is not 
required. Results from our research will be disseminated at 
relevant (inter- )national conferences and via publication in 
peer- reviewed journals. Synthesising evidence on end- of- 
life care preferences of older patients with multimorbidity 
will improve shared decision- making and satisfaction in 
this final period of life.
PrOsPErO registration number CRD42020151862.
IntrOduCtIOn
Multimorbidity, or the presence of multiple 
coexisting chronic diseases or conditions,1 
affects the majority of older adults2 and 
is associated with increased mortality and 
healthcare usage.3–5 In addition, multimor-
bidity negatively impacts quality of life and 
increases symptom burden.6–8 Evidence is 
therefore required on how to best manage 
multimorbid patients.9 10
The care of patients with multimorbidity 
entails complex medical decision- making 
especially at the end of life (EoL). EoL care 
refers not only to the healthcare services that 
are provided to patients in the final hours or 
days of their lives, but, more broadly, to those 
provided to all patients whose conditions have 
become advanced, progressive and incur-
able.11 12 EoL care must be embedded within 
the context of patient preferences, so the care 
that the multimorbid patients receive during 
the final days of their lives is concordant with 
the care they desire. However, individuals with 
multimorbidity often have to make numerous 
and conflicting decisions and choices, which 
makes eliciting their preferences rather chal-
lenging. The provision of effective EoL care 
to those with multimorbidity is impossible 
strengths and limitations of this study
 ► This is the first systematic review on end- of- life care 
preferences of patients with multimorbidity and will 
provide an important body of evidence to support 
the consideration of patient- centred care in end- of- 
life care policy.
 ► A multinational and multidisciplinary team with con-
siderable methodological experience and skills will 
provide the necessary expertise.
 ► A patient representative has been involved in de-
signing the study to ensure that from the beginning, 
patient- relevant questions are assessed, and results 
discussed accordingly.
 ► The main study limitations are the poor indexing of 
articles and the missing or non- standardised defini-
tion of ‘patient preferences’.
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without cooperation between palliative care providers, 
speciality care and primary care. In fact, EoL care is 
an essential task performed by most of the healthcare 
providers and it often involves decision- making about 
how and where the patients want to receive care.
According to recent studies that were not confined 
to patients with multimorbidity, most adults’ EoL care 
preferences (eg, for cardiopulmonary resuscitation) 
are stable over time and independent of their health 
status.13 A systematic review of where the adult patients 
would prefer to die revealed that most of the people 
would prefer to die at home and that such preferences 
are independent of changes in health status.14 These 
results were confirmed in another systematic review15 
on adults with diverse health conditions. However, it 
was unclear what proportion of people preferred home 
when the underlying condition was taken into account 
(eg, cancer vs non- cancer conditions).15 Furthermore, 
considerable heterogeneity between and within popu-
lation groups exists, both in the proportion of patients 
whose preferences change over time and in the direction 
of such changes (eg, towards or away from more aggres-
sive care).10 13
Multimorbidity is positively associated with the desire 
not to be resuscitated, but this finding depends on the 
nature of the morbidities. Cognitive impairment, stroke 
and cancer were very positively associated with the 
desire not to be resuscitated, while heart diseases were 
not.16 However, we have no information on the prefer-
ences of patients with a mix of disabling/life- threatening 
conditions or an accumulation of several conditions. 
To the best of our knowledge, no systematic review has 
focussed on EoL care preferences of older patients with 
multimorbidity.
To provide decision support to healthcare providers 
and assist this complex patient population in an emotion-
ally difficult situation, we aim to systematically review EoL 
care preferences of older patients with multimorbidity. 
We will base the review on a knowledge cluster of EoL 
care preferences that we identified in an evidence map 
we previously developed on health- related preferences 
in older patients with multimorbidity.17 The systematic 
review is the natural next step and will allow us to synthe-
sise current knowledge of EoL care preferences and help 
prioritise and guide future innovations in EoL care policy.
MEthOds And AnAlysIs
The present protocol will follow the Preferred Reporting 
System Items for Systematic Review and Meta- Analysis 
Protocols (PRISMA- P) checklist18 (see online supplemen-
tary additional file 1).
design
Mixed- methods systematic review using the convergent 
integrated approach in which data is transformed in 
such a way that quantitative and qualitative data can be 
combined and the synthesis of quantitative and qualita-
tive studies simultaneously occurs.19
Criteria for considering studies for this review
Types of studies
We will include primary studies that use quantitative (eg, 
questionnaires), qualitative (eg, interviews, focus groups) 
and mixed- methods methodologies. Systematic reviews 
and meta- analyses will not be included, but if a systematic 
review is relevant to our topic we will screen its reference 
list for potentially eligible studies that were not identified 
in our systematic literature searches (see the section on 
search methods used to identify studies).
We will exclude case reports and articles, such as confer-
ence abstracts, narrative reviews and editorials.
Types of participants
We will include older patients (mean or median age ≥60 
years20) with multimorbidity (two or more simultaneous 
chronic conditions).1 Studies focussing on patients with 
one chronic disease will be included when authors have 
reported on at least one additional chronic condition in 
the majority of the study population.
Studies addressing only the preferences of caregivers, 
family members and healthcare professionals will be 
excluded. Studies confined to population- based and 
general public perspectives will also be excluded.
Phenomenon of interest
Our phenomenon of interest will focus on EoL care pref-
erences, defined as preferences related to the care that 
should be provided in the final period of life, regardless 
of whether it may, in some cases, be provided for months 
or even years.12 EoL care preferences will comprise (i) 
willingness to receive life- sustaining treatments (eg, 
percentage of people with preferences for or against 
cardiopulmonary resuscitation, intubation and mechan-
ical ventilation, intensive care, intravenous nutritional 
support, nasogastric tube feeding and/or dialysis with-
drawal), (ii) willingness to opt for palliation of symptoms, 
(iii) the place where patients would prefer to receive EoL 
care (eg, percentage of people that would prefer to die 
at home) and (iv) interest in participating in a shared 
decision- making process related to EoL care.
We will exclude studies investigating preferences for or 
against interventions of limited availability or whose legal 
status is unclear (eg, preferences for or against eutha-
nasia or physician- assisted suicide) as such approaches 
are deemed outside the scope of this review. We will 
also exclude studies exploring patients’ will to live. (see 
table 1)
search methods used to identify studies
Electronic searches
We will search the following electronic sources from 
inception using a combination of Medical Subject Head-
ings and keywords: MEDLINE, CINAHL, PsycINFO, 
Social Sciences Citation Index, Social Sciences Citation 
Index Expanded, PSYNDEX and The Cochrane Library. 
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Quantitative (observational and interventional) and qualitative 
studies addressing end- of- life care preferences from the patient’s 
perspective
 ► Age: average/median age of 60 or older, geriatric patients, elderly 
patients
 ► Multimorbidity: two or more simultaneous chronic conditions
 ► Setting: We will not apply restrictions to geographical location, 
country or healthcare context
 ► No restrictions to the date of publication or language of the study
 ► Case reports
 ► Articles without details of methods
 – Conference abstracts
 – Narrative reviews
 – Editorials
 ► Studies investigating preferences for or against interventions 
that are not generally available or only legal in limited 
contexts (eg, euthanasia)
 ► Studies only addressing preferences of caregivers, family 
members and healthcare professionals
 ► Population- based studies (public health perspective)
Table 2 Search for end- of- life care preferences. (13 September 2019 – MEDLINE via Ovid (medall))
1. ((advanced OR incurabl* OR progressive OR life- limiting OR fatal OR serious* OR end- stage OR terminal*) 
adj3 (disease OR condition OR illness OR ill OR morbid*)).ti,ab,kf.
End- of- Life
2. (End of life OR (last days adj3 life) OR (last year* adj3 life) OR (last week* adj3 life) OR (last month* adj3 
life) OR (last days adj3 live) OR (last week* adj3 live) OR (last month* adj3 live) OR (last year* adj3 live) OR 
imminent death OR (close adj3 death) OR before death OR palliative).ti,ab,kf.
End- of- life
3. (Terminal Care OR Terminally Ill OR Hospice Care OR Life Support Care OR Advanced Cardiac Life Support 
OR Palliative Care).sh.
  
4. or/1–3   
5. (Comorbidity OR Multimorbidity OR Multiple Chronic Conditions).sh. Multimorbidity
6. ((comorbid* OR multiple OR several OR multi OR concurrent OR complex OR more than one) adj4 (disease* 
OR condition* OR illness* OR morbid*)).ti,ab,kf.
  
7. (Comorbidit* OR multimorbidit* OR multidisease* OR polymorbid* OR frail*).ti,ab,kf.   
8. or/5–7   
9. 4 AND 8   
10. (scale OR scaling OR ranking OR rating OR conjoint- analysis OR conjoint- analyses OR contingent valuation 
OR analytic hierarch* process* OR time trade off OR evidential reasoning OR multi- attribute utility OR maut 
OR multiattribute decision model OR madm OR electre iv OR electre is OR visual analog* scale OR score* 
OR scoring OR standard gamble OR EVIDEM OR paprika method OR simple additive weighting method 
OR weighted product method OR wpm OR technique for order preference by similarity to ideal solution OR 
topsis OR analytic network process OR anp OR todim OR macbeth OR smart OR focus group* OR interview* 
OR questionnair* OR choice).ti,ab,kf.
Methods to elicit 
Preferences
11. (prefer* OR wish* OR need OR needs OR value* OR belief* OR want* OR desire* OR priorit* OR attitude* OR 
perception* OR evaluation* OR choice* OR experience* OR decision* OR decide* OR perspective*).ti,ab,kf.
Preferences
12. (patient* OR women* OR men* OR elder* OR old* OR frail*).ti,ab,kf.   
13. 10 AND 11 AND 12   
14. (Patient Satisfaction OR Patient Preference OR Health Priorities OR Needs Assessment OR Advance Care 
Planning OR Advance Directives).sh.
  
15. 9 AND 13   
16. 9 AND 14   
17. or/15–16 2176 articles 
retrieved
To avoid publication bias, we will not apply any restric-
tions to publication date or language.
We will follow the recommendations of PRESS (Peer 
Review of Electronic Search Strategies) and develop 
the final search strategy in collaboration with an expert 
medical science librarian.21
The electronic search strategy for the MEDLINE data-
base from inception to September 2019 is provided in 
table 2. This search strategy will be adapted for use in the 
other databases.
Searching other resources
We will identify potentially eligible studies that are not 
captured by our electronic database searches by exam-
ining the reference lists of included studies, relevant 
systematic reviews and meta- analyses, and by carrying out 
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searches of cited references (forward and backward cita-
tion tracking) using the Web of Science Core Collection.
study records
Data management
Bibliographic details of all identified references will be 
uploaded to EndNote first and then converted into Covi-
dence for title, abstract and full- text screening. Duplicates 
will be removed.
Selection of studies
Each of the two review authors (AIG- G and JN) will 
independently screen the title and the abstract of each 
identified study to determine which should be assessed 
further. Before screening, a stepwise calibration exercise 
will be performed on a sample of 30 studies,22 with the 
aim of achieving 80% agreement between the reviewers. 
In case 80% agreement is not reached, our inclusion and 
exclusion criteria will be refined and the calibration will 
be repeated until the threshold is met. We will report 
any changes to the inclusion and exclusion criteria that 
result from the calibration exercise as deviations from the 
published protocol. The full text of potentially eligible 
papers will then be retrieved and independently assessed 
for eligibility by the two reviewers (AIG- G and JN). Any 
discrepancy will be resolved through discussion and 
consensus by a third reviewer (CS).
We will present a PRISMA flowchart of study selection.23
Data collection
One review author (AIG- G) will extract key study and 
participant characteristics from all studies that fulfil the 
inclusion criteria and report data on the phenomenon of 
interest. The second review author (CS) will cross- check 
the extracted data. Any disagreement will be resolved by 
discussion, or, if necessary, by a third author (CM).
Data items
We will stratify data extraction according to the study 
type. Using standard extraction templates in Excel and 
Access datasheets, data will be extracted under the 
following headings: Study reference (ie, first author, year 
of publication, country of study origin); Study aim; Study 
setting; Sample size; Population characteristics (eg, age, sex, 
definition of multimorbidity, prognosis or illness severity, 
cancer or non- malignant condition); Preference- assessment 
method (eg, interview or questionnaire, number of assess-
ments, time between assessments if applicable); Context 
of preference (ie, hypothetical/real, preference- sensitive 
situation); Information provided by the authors on the presen-
tation of alternatives (eg, negative or positive framing);24 25 
Description of phenomenon of interest (EoL care elements that 
study participants were queried about, for example, resus-
citation preference); and Results concerning the described 
phenomenon of interest (eg, proportion of participants 
expressing a preference for a specific type of EoL care) 
(table 3).
Dealing with duplicate and associated publications
In the event of multiple reports (publications) of a 
primary study, we will maximise the yield of information 
by collating all available data and using the most complete 
data set, aggregated across all known publications.
Assessment of risk of bias in included studies
A risk of bias (RoB) assessment will be conducted using 
the Mixed- Methods Appraisal Tool (MMAT),26 whereby 
one author (AIG- G) will apply the MMAT criteria and 
a second author (CS) will verify the assessments. Both 
authors will discuss the impact of the RoB assessments 
on further analyses and involve a third author (CM) in 
cases of dissent. If an important RoB is detected, sensi-
tivity analyses will be performed that exclude studies with 
a high RoB.
data synthesis
We will conduct a mixed- methods systematic review using 
a convergent integrated approach in accordance with 
Joanna Briggs Institute methodology19 that will (i) synthe-
sise qualitative data by means of thematic synthesis, (ii) 
synthesise quantitative data and perform meta- analysis 
if applicable, and in a final step, (iii) synthesise and 
integrate both (i) and (ii) following the methodology 
described by Sandelowski et al and Pearson et al.27 28 More 
specifically, the approach will include the following steps:
i. Qualitative analysis and synthesis: Both reviewers 
(AIG- G and CS) will independently analyse the ex-
tracted data and provide thematic codes. In order to 
derive a matrix structure, both reviewers will discuss 
coding and identify overarching thematic issues and 
categories with the help of MaxQDA 18 software.29 30
ii. Quantitative analysis: Data from interventional and 
observational studies will be analysed separately. 
The meta- analysis of data will be considered in stud-
ies that have provided comparable and sufficiently 
homogeneous outcomes. We will first assess hetero-
geneity qualitatively (in terms of study design, pop-
ulation and the phenomenon of interest). Assuming 
the qualitative assessment does not preclude meta- 
analyses of studies, we will also assess heterogeneity 
by means of X2 and additional tests. If a meta- analysis 
is impossible, a descriptive analysis will be carried out.
iii. Mixed- methods data synthesis (integrated synthesis 
methodology27 28): To synthesise qualitative and quan-
titative data, three reviewers (AIG- G, CS and CM) will 
decide which is the most promising compatible for-
mat based on the results of (i) and (ii), whereby the 
decision will depend mainly on the number of qual-
itative and quantitative studies that are eligible for 
inclusion. Afterwards,27 data will either be classified 
according to subject matter (resulting in data synthe-
sis by means of meta- aggregation) or by converting 
qualitative data into a numerical format (resulting 
in a quantitative synthesis using meta- analytical ap-
proaches).27 28 31 32
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Table 3 Data extraction framework
Bibliometrics Description Coding
Study identification First author, year of publication (journal’s description)
Study characteristics Study aim (authors’ description)
Geographical location Country
Study setting Inpatient, outpatient
Type of study Observational (ie, qualitative, quantitative cross- 
sectional, quantitative longitudinal, mixed methods) 
or interventional study
Patient characteristics Sample size Number of patients
Age (years)
Sex (% females)
Definition of multimorbidity (authors’ description)
Prognosis or illness severity indices (if 
applicable)
eg, less than 6 months of life or congestive heart 
failure NYHA II- IV
Type of index condition (if applicable) Cancer or non- malignant
Methods of data collection Type of data collection Interview, semi- structured interview, survey, focus 
group, questionnaire (authors’ description)
Context of the preference Hypothetical / real preference- sensitive situation*
Presentation of information on alternatives - 
Framing effect†
High- risk of positive- negative framing, low risk of 
framing or unclear
  Number of assessments eg, one assessment if cross- sectional, two or more 
assessments if longitudinal
Time between assessments If applicable
Phenomenon of interest Description Type of EoL preference queried for example, 
cardiopulmonary resuscitation
  Results eg, percentage of participants for or against life- 
sustaining treatments (number of participants 
stating a preference out of all the patients included 
in the study)
Results / Conclusions   (authors’ description)
*Hypothetical preference- sensitive situation: EoL care preferences are measured by asking study participants to imagine themselves in 
a situation in the future that requires such care; Real preference- sensitive situation: EoL care preferences are measured by asking study 
participants to state their preferences in a context that actually requires them to express a preference for such care. Examining preferences 
using hypothetical scenarios removes the acute stress of making decisions when confronted with an EoL situation.
†Framing effect: Cognitive bias caused by the influence of the way information is presented on the choices people make.
EoL, End of Life; NYHA, New York Heart Association.
Planned sensitivity and subgroup analysis
If the available data allows, we will conduct sensitivity 
analyses that exclude studies at high risk of bias in order 
to determine its impact. In addition, we plan to conduct 
subgroup analyses to examine whether EoL care prefer-
ences are affected by sex, specific preference assessment 
contexts (hypothetical or real scenarios), the type of 
advanced disease (cancer or non- malignant) and patient 
prognosis or illness severity. If the included studies do not 
permit quantitative synthesis, we will descriptively report 
on evidence relating to the above- mentioned aspects.
timeline for review
At the time of this submission we have already completed 
electronic searches, piloted the study selection process 
and started formally screening search results with respect 
to the eligibility criteria. This systematic review is sched-
uled to end in August 2020.
Patient and public involvement
A patient representative (KR) from the Federal Joint 
Committee ‘Gemeinsamer Bundesausschuss (G- BA)’ 
actively participated in the design of the systematic 
review. He was involved in defining the research question, 
selecting the methodology to be used and the data to be 
collected, as well as selecting the phenomenon of interest. 
KR will also be involved in the analysis and interpretation 
of the findings, crafting the overall message, the develop-
ment of recommendations and in the dissemination of 
the results. KR has considerable experience in evidence- 
based medicine and an understanding of the pivotal role 
of patients’ preferences in the provision of healthcare. 
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The G- BA is the ultimate decision- making body for the 
joint self- administration of stakeholders in the German 
health service and the statutory health insurance service 
catalogue for over 70 million insured individuals is based 
on its guidelines.
EthICs And dIssEMInAtIOn
Due to the nature of the proposed systematic review, ethics 
approval is not required. We will disseminate our study 
findings to healthcare providers and patients and present 
them at relevant national and international conferences. 
We also aim to publish the results of the study in a peer- 
reviewed journal.
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